Castle Biosciences (CSTL) Amortization - Intangibles (2021 - 2026)

Castle Biosciences has disclosed Amortization - Intangibles across 6 years of filings, most recently posting $2.2 million for Q1 2026.

• Amortization - Intangibles for Q1 2026 came in at $2.2 million, down 92.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.7 million (down 75.17% YoY), and the FY2025 annual result was $34.8 million, up 213.51% from the prior year.
• Amortization - Intangibles came in at $2.2 million for Q1 2026 at Castle Biosciences, down from $2.2 million in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $28.3 million in Q1 2025 to a low of $1.6 million in Q1 2022.
• The 5-year median for Amortization - Intangibles is $2.2 million (2025), against an average of $3.7 million.
• Across the five-year window, Amortization - Intangibles soared 1187.5% in 2025 and tumbled 92.23% in 2026, its largest moves.
• Castle Biosciences' Amortization - Intangibles stood at $2.2 million in 2022, then grew by 6.19% to $2.3 million in 2023, then dropped by 8.7% to $2.1 million in 2024, then climbed by 6.57% to $2.2 million in 2025, then dropped by 1.7% to $2.2 million in 2026.
• The last three Amortization - Intangibles figures came in at $2.2 million (Q1 2026), $2.2 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.